Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
Imfinzi regimen demonstrated statistically significant DFS improvement in high-risk NMIBC in POTOMAC Ph 3 trial May 13, 2025
Preliminary Clinical Data for CT0596 Announced, Demonstrating Favorable Safety and Efficacy May 13, 2025
Elironrasib monotherapy demonstrated acceptable tolerability and encouraging initial antitumor activity in previously treated G12C NSCLC patients May 13, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
CR achieved after 1 month of the in vivo CD19 CAR-T treatment, with durable response sustained over three months in R/R DLBCL patients May 6, 2025
Higher Exposure of AFM24 Associated with Significantly Higher Response Rates and PFS in Refractory NSCLC Patients May 6, 2025
Tuspetinib-based Triplet regimen in 1L AML Patients in Ph 1/2 TUSCANY Trial Demonstrates Safety, Complete Remissions May 6, 2025
Initial Data from Ph 3 Trial Demonstrating 75% CRR at 3 Months with nadofaragene firadenove) in BCG-unresponsive Japanese NMIBC Patients Announced April 30, 2025
Ivonescimab + Chemo combo yields Statistically Significant PFS vs. Tislelizumab + Chemo in Chinese Patients with 1L Squamous NSCLC in HARMONi-6 Study April 30, 2025
Sasanlimab Combination Significantly Improves EFS in BCG-Naïve, High-Risk NMIBC, but misses OS endpoint April 30, 2025
Positive Interim Results Demonstrating Durable Responses in Ongoing Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC Announced April 30, 2025
New long-term PFS data projections reinforce SC DARZALEX quadruplet therapy as a foundational SoC for patients with newly diagnosed multiple myeloma April 30, 2025
TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC April 30, 2025
TAR-200 monotherapy demonstrates highest CRR reported to date with sustained clinical benefits in patients with certain types of bladder cancer April 30, 2025
Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC April 30, 2025
OLYMPUS Long-Term Follow-Up shows Nearly 4-Year DoR in Patients with LG-UT Urothelial Cancer Who Achieved a Complete Response to prior JELMYTO Treatment April 30, 2025
Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec announced April 30, 2025
FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints April 30, 2025
